Press Releases

Investor Alerts

Sep 12, 2019

Satsuma Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
Sep 3, 2019

Satsuma Pharmaceuticals Announces Poster Presentations at the International Headache Congress
Sep 3, 2019

Satsuma Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock
Aug 22, 2019

Satsuma Pharmaceuticals Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
Jul 8, 2019

Satsuma Pharmaceuticals Announces Presentation of STS101 (Dihydroergotamine Nasal Powder) Phase 1 Trial Results at American Headache Society's Annual Scientific Meeting

-- Favorable Pharmacokinetic, Safety, and Tolerability Results Support Advancing STS101 into Pivotal Phase 3 Efficacy Trial

Show per page